Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Transitional Cell 1

Interventions

fludarabine phosphate 43Whole-Body Irradiation 36Mycophenolic Acid 36Peripheral Blood Stem Cell Transplantation 31Cyclophosphamide 31Tacrolimus 28Busulfan 22Antilymphocyte Serum 21Cyclosporine 19fludarabine 17ruxolitinib 16Melphalan 16Methotrexate 15Cytarabine 12thymoglobulin 9Sirolimus 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Filgrastim 8Cyclosporins 8Radiotherapy 7Cord Blood Stem Cell Transplantation 7Rituximab 6Alemtuzumab 6merphos 5Stem Cell Transplantation 5Flow Cytometry 5Azacitidine 5sargramostim 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloproliferative Disorders × Interleukin-7 × Clear all
NCT03941769 2024-10-17

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

M.D. Anderson Cancer Center

Phase 1/2 Completed
1 enrolled 5 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡